baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Zai Lab Ltd/ US98887Q1040 /

2024-07-31 6:28:59 PM	Chg. +0.8100	Volume	Bid6:32:53 PM	Ask6:32:53 PM	High	Low
19.1800USD	+4.41%	155,885 Turnover: 2.11 mill.	19.1600Bid Size: 400	19.2000Ask Size: 200	19.4900	18.8050

GlobeNewswire 06-01 Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipa...

GlobeNewswire 05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 04-18 Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated P...

GlobeNewswire 04-10 Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first...

GlobeNewswire 03-06 Crescendo Biologics to present at the 2024 AACR Annual Meeting

GlobeNewswire 03-05 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...

GlobeNewswire 02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report

GlobeNewswire 01-16 Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretar...

GlobeNewswire 01-08 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 01-04 Former Biogen CEO Michel Vounatsos Joins Quris-AI Board

GlobeNewswire 2023-12-13 Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug L...

GlobeNewswire 2023-12-06 Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307...

GlobeNewswire 2023-11-07 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

GlobeNewswire 2023-10-31 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-10-26 Zai Lab Announces Participation in November Investor Conferences

GlobeNewswire 2023-10-18 Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7,...

GlobeNewswire 2023-10-05 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023

GlobeNewswire 2023-09-21 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.

GlobeNewswire 2023-09-18 Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...

GlobeNewswire 2023-09-18 Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injec...

GlobeNewswire 2023-09-12 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...

GlobeNewswire 2023-09-07 Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...

GlobeNewswire 2023-09-04 Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...

GlobeNewswire 2023-08-30 Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patien...

Zai Lab Ltd/ US98887Q1040 /

If you wish to receive reply to your feedback, please provide your email address.